Literature DB >> 7488031

Hyperphosphorylation of the cytoskeletal protein Tau by the MAP-kinase PK40erk2: regulation by prior phosphorylation with cAMP-dependent protein kinase A.

R Raghunandan1, V M Ingram.   

Abstract

PK40erk2 is a MAP kinase which phosphorylates recombinant hTau40 up to 14 moles of phosphate/mole, markedly slowing its electrophoretic mobility. PK40erk2 acting on TAU is expected to cause the appearance of Alzheimer's disease-specific phosphoepitopes, detectable by specific antibodies. Maximal phosphorylation in vitro of hTau40 by PKAcat incorporates only 2-3 moles of phosphate/mole. Consequent, but smaller, reduction in electrophoretic mobility is seen, but not the formation of Alzheimer-specific or hyperphosphorylation-specific epitopes. Phosphorylation of hTau40 by PKAcat sharply reduces the number of phosphates that can now be introduced by PK40erk2 to 5-6 moles/mole, instead of the expected 11 moles/mole. Thus, prior phosphorylation by PKA, a non-proline-directed protein kinase, regulates the conformation of the protein substrate Tau so as to make some sites very much less accessible to phosphorylation by the proline-directed kinase, PK40erk2.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7488031     DOI: 10.1006/bbrc.1995.2571

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Hyperactivation of mitogen-activated protein kinase increases phospho-tau immunoreactivity within human neuroblastoma: additive and synergistic influence of alteration of additional kinase activities.

Authors:  F J Ekinci; T B Shea
Journal:  Cell Mol Neurobiol       Date:  1999-04       Impact factor: 5.046

2.  Phosphorylation of tau alters its association with the plasma membrane.

Authors:  F J Ekinci; T B Shea
Journal:  Cell Mol Neurobiol       Date:  2000-08       Impact factor: 5.046

Review 3.  Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.

Authors:  Michy P Kelly
Journal:  Cell Signal       Date:  2017-11-23       Impact factor: 4.315

4.  The order of exposure of tau to signal transduction kinases alters the generation of "AD-like" phosphoepitopes.

Authors:  T B Shea; C M Cressman
Journal:  Cell Mol Neurobiol       Date:  1999-04       Impact factor: 5.046

5.  Protein kinase C and calcium/calmodulin-dependent protein kinase II phosphorylate three-repeat and four-repeat tau isoforms at different rates.

Authors:  T J Singh; I Grundke-Iqbal; W Q Wu; V Chauhan; M Novak; E Kontzekova; K Iqbal
Journal:  Mol Cell Biochem       Date:  1997-03       Impact factor: 3.396

6.  Pituitary adenylate cyclase-activating polypeptide prevents the effects of ceramides on migration, neurite outgrowth, and cytoskeleton remodeling.

Authors:  Anthony Falluel-Morel; David Vaudry; Nicolas Aubert; Ludovic Galas; Magalie Benard; Magali Basille; Marc Fontaine; Alain Fournier; Hubert Vaudry; Bruno J Gonzalez
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-04       Impact factor: 11.205

7.  The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer's disease.

Authors:  S Illenberger; Q Zheng-Fischhöfer; U Preuss; K Stamer; K Baumann; B Trinczek; J Biernat; R Godemann; E M Mandelkow; E Mandelkow
Journal:  Mol Biol Cell       Date:  1998-06       Impact factor: 4.138

8.  Activation of Ras-ERK Signaling and GSK-3 by Amyloid Precursor Protein and Amyloid Beta Facilitates Neurodegeneration in Alzheimer's Disease.

Authors:  Lisa Kirouac; Alexander J Rajic; David H Cribbs; Jaya Padmanabhan
Journal:  eNeuro       Date:  2017-03-27

9.  Phosphorylation and Dephosphorylation of Tau Protein by the Catalytic Subunit of PKA, as Probed by Electrophoretic Mobility Retard.

Authors:  María J Benítez; Raquel Cuadros; Juan S Jiménez
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

10.  microRNA-208a in an early stage myocardial infarction rat model and the effect on cAMP-PKA signaling pathway.

Authors:  Gao Feng; Zhang Yan; Chuanchuan Li; Yuemei Hou
Journal:  Mol Med Rep       Date:  2016-06-14       Impact factor: 2.952

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.